• Mutation; HGNC; HGNC:427; ALK; Simple; p.Lys1491Arg (c.4472A>G); ClinVar=VCV000133474; Zygosity=Unspecified (PubMed=30991738).
  
• Mutation; HGNC; HGNC:7773; NF2; Simple; p.Asp213fs (c.639delC); Zygosity=Unspecified (PubMed=30991738).
  
• Mutation; HGNC; HGNC:9585; PTCH1; Simple; p.Pro1164Leu (c.3944C>T); ClinVar=VCV000041663; Zygosity=Unspecified (PubMed=30991738).
  

PubMed=30991738; DOI=10.3390/cancers11040545; PMCID=PMC6521001
Jungwirth G., Yu T., Moustafa M., Rapp C., Warta R., Jungk C., Sahm F., Dettling S., Zweckberger K., Lamszus K., Senft C., Lohr M., Kessler A.F., Ketter R., Westphal M., Debus J., von Deimling A., Simon M., Unterberg A., Abdollahi A., Herold-Mende C.
Identification of KIF11 as a novel target in meningioma.
Cancers (Basel) 11:545.1-545.18(2019)

PubMed=34885009; DOI=10.3390/cancers13235898; PMCID=PMC8657092
Yu T., Cao J.-G., Alaa Eddine M., Moustafa M., Mock A., Erkut C., Abdollahi A., Warta R., Unterberg A., Herold-Mende C., Jungwirth G.
Receptor-tyrosine kinase inhibitor ponatinib inhibits meningioma growth in vitro and in vivo.
Cancers (Basel) 13:5898.1-5898.16(2021)